
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The FDA has added BAY 43-9006, an investigational treatment for metastatic renal cell carcinoma, to its fast track program.





